Related Experiment Video

Updated: Jun 3, 2026

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae
12:13

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Published on: April 5, 2015

Systems pharmacology assessment of the 5-fluorouracil pathway

Filipe A Muhale1, Barbara A Wetmore, Russell S Thomas

  • 1UNC Institute for Pharmacogenomics & Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599-7361, USA.

Pharmacogenomics
|April 1, 2011
PubMed
Abstract

Insights

Researchers identified 13 key genes impacting 5-fluorouracil (5-FU) drug sensitivity in colorectal cancer cells. This study validates RNA interference screening for prioritizing pharmacogenomic targets, aiding future drug development.

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Cancer Research

Background:

  • 5-fluorouracil (5-FU) is a critical chemotherapy agent.
  • Understanding 5-FU drug-pathway genes is essential for optimizing cancer treatment.
  • Identifying genetic factors influencing drug response can personalize therapy.

Purpose of the Study:

  • To evaluate the impact of 5-fluorouracil (5-FU) pathway genes on drug cytotoxicity.
  • To determine if loss-of-function analyses can prioritize pharmacogenomic candidate genes.

Main Methods:

  • Dose-response experiments were conducted on three human colorectal cell lines.
  • Specific gene knockdown was performed using RNA interference (RNAi).
  • Changes in 5-FU sensitivity were quantified by measuring IC(50) values.

Main Results:

  • Thirteen out of 24 analyzed genes significantly altered 5-FU sensitivity.
  • Key genes identified include DHFR, TYMS, and RRM1.
  • Significant changes in IC(50) were observed for genes like DPYS, DUT, and FPGS.

Conclusions:

  • RNAi screening effectively prioritized genes within the 5-FU drug pathway.
  • The identified genes are potential pharmacogenomic targets for 5-FU therapy.
  • Further validation using clinical samples is recommended.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...